secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001171843-24-001791
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience receives $3.1M ERC cash in Q1, expects another $3.1M; amends credit EBITDA addbacks
--------------------------------------------------------------------------------

- Received $3.1M cash in Q1 2024 from employee retention credits (ERC); expects additional $3.1M in FY2024.
- Will incur ~$1M commission fee on ERC; credit agreement amended to exclude fee and $600K escheatment reserves from EBITDA cap.
- Third amendment to credit agreement allows add-backs beyond 10% EBITDA cap for those specific items, easing covenant compliance.
- No fees payable for amendment except reimbursable attorney costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324001791/0001171843-24-001791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324001791/f8k_040324.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer